Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients

Name: Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients
Creator: Joseph Stoll
Published: 2021-01-28T06:02:30.292Z
Keywords: Dermatology

Stoll, Joseph; Battle , Laura; Moy , Andrea; Dusza , Stephen; Park, Jae; Tallman, Martin; Taylor, Justin; Markova, Alina

doi:10.17632/kyf2cnsxjw.1

Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients

Published: 28 January 2021| Version 1 | DOI: 10.17632/kyf2cnsxjw.1

Contributors:

Joseph Stoll, Laura Battle , Andrea Moy , Stephen Dusza , Jae Park, Martin Tallman, Justin Taylor, Alina Markova

Description

Supplemental Figure 1. Proposed management guidelines for CPX-351-associated purpuric rash. mg, milligrams; kg, kilograms

Files

Institutions

Memorial Sloan Kettering Cancer Center

Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients

Description

Files

Institutions

Categories

Licence